Patent ID: 11918622
Assignee: MAIA PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 8:
9. A method of inhibiting blood clots in a patient in need thereof comprising intravenously administering to the patient a therapeutically effective amount of a ready-to-use liquid composition comprising about 5 mg/mL bivalirudin or a salt thereof, about 0.8 mg/mL sodium acetate trihydrate, about 100 mg/mL PEG 400, and water, wherein
the ready-to-use liquid composition is prepared by a method that comprises mixing bivalirudin or salt thereof, sodium acetate, PEG 400, and water,
the composition does not comprise sodium chloride or dextrose, and
the composition has a pH of from greater than 5.0 to 5.7.